Fertilizer and crop-input stocks occupy a strategically important position in markets because farmers must sustain or increase yields while arable-land growth remains limited. Global food, feed and biofuel demand keeps the underlying need for nutrients, seeds, crop protection and agronomy services firmly in view. The group is not insulated from cycles: fertilizer prices, natural-gas costs, planting acreage and trade policy can all move earnings sharply. Still, the sector offers exposure to an essential stage of the agricultural economy, with businesses ranging from commodity-sensitive producers to more farmer-facing platforms.
The opportunity set spans several distinct businesses. Nutrien’s 2025 annual report identifies a $127 billion crop-input market and describes a Retail segment that distributes nutrients, crop protection products, seed and services directly to farmers. Upstream names provide leverage to nitrogen, phosphate and potash pricing, while companies such as Corteva and FMC focus on seed genetics, seed treatments and crop protection. Scotts Miracle-Gro adds branded lawn, garden and indoor-growing products. Mosaic, meanwhile, describes itself as a leading producer and marketer of concentrated phosphate and potash crop nutrients.
This countdown ranks seven US-listed fertilizer and crop-input stocks by investment quality, moving from rank #7 to the best-ranked name at #1. The list includes both financially challenged recovery situations and businesses with stronger profitability, diversification or recent operating momentum. Corteva’s announced plan to separate its Seed and Crop Protection businesses into two standalone public companies is another important development to monitor, because the transaction could make valuation comparisons across the input value chain more transparent.
Our ranking emphasizes investment quality rather than simply the lowest valuation or the greatest commodity exposure. We screened the US-listed universe for fertilizer and crop-input companies with market capitalization above $500 million, then assessed composite quality grades alongside profitability, balance-sheet indicators, valuation, growth, earnings delivery and analyst sentiment. Primary-source company descriptions and financial data supplied the business context. Because this is a countdown, the strongest overall combination is intentionally reserved for #1 at the end rather than presented upfront.
What they do. The company sells lawn and garden products, including lawn fertilizers, grass seed, spreaders, weed and pest controls, plant foods, soils, mulches and live goods. It also markets indoor and hydroponic gardening products, lighting systems and household pest-control products through brands including Scotts, Turf Builder, Miracle-Gro, Ortho and Roundup. Its revenue model is primarily branded consumer-product sales through home centers, mass merchants, hardware stores, nurseries, e-commerce platforms and specialty indoor-gardening channels.
Why it fits.SMG gives the theme a downstream, consumer-facing angle rather than direct exposure to farm-scale potash, phosphate or nitrogen markets. Its fertilizer, seed, crop-protection and plant-food portfolio connects with the broader crop-input stack, while its branded distribution model can make demand less directly dependent on commodity fertilizer prices. The trade-off is that lawn, garden and indoor-growing spending is more discretionary than staple agricultural applications.
Numbers that matter. Revenue grew just 1.1% year over year, while earnings declined 25.5%. The company reported a 32.2% gross margin and a 16.83% operating margin, but its 2.12% net margin and negative 47.64% ROE point to a much weaker bottom line and capital profile. Trailing P/E was 23.529, compared with a forward P/E of 14.9031, and TTM EPS was $2.59 versus an estimated next-year EPS of $4.7255. That valuation gap depends heavily on the expected earnings recovery.
Recent momentum.SMG beat EPS estimates in 6 of the last 8 reported quarters. On July 29, 2026, EPS was $2.82 versus an estimate of $2.53, an 11.5% surprise; the prior April quarter also beat by 13.0%. Analysts’ breakdown was 1 Buy and 3 Holds, with no reported Sell count, supporting a cautious rather than enthusiastic consensus. The recent earnings beats help the case for normalization, but the weak net margin keeps SMG at the bottom of this quality-ranked list.
What they do.FMC develops, markets and sells crop-protection chemicals across Latin America, North America, Europe, the Middle East, Africa and Asia. Its portfolio includes insecticides, herbicides and fungicides, alongside biologicals, crop nutrition and seed-treatment products. The company sells through its own organization, alliance partners, independent distributors and sales representatives, giving it international reach across both established and emerging agricultural markets.
Why it fits.FMC is a focused way to access the crop-protection portion of the theme. Insecticides, herbicides, fungicides and seed treatments address yield preservation and crop health, complementing the nutrient exposure offered by fertilizer producers. Its geographic breadth can diversify the customer base, but the business remains exposed to farmer economics, product demand, channel inventories, regulatory conditions and pricing pressure in agricultural chemicals.
Numbers that matter.FMC’s revenue fell 17.5% year over year and earnings declined 77.6%, while TTM EPS was negative $21.49. Gross margin was 31.9% and operating margin was 11.83%, but the company posted a negative 84.83% net margin and negative 88.38% ROE. The forward P/E of 9.311 looks modest on expected earnings, yet the lack of a usable trailing P/E and the severe net loss make that multiple highly dependent on a turnaround. EBITDA was $269.3 million against revenue of $3.2512 billion.
Recent momentum. The earnings record is better than the full-year growth numbers: FMC beat estimates in 7 of the last 8 reported quarters. Its July 29, 2026, EPS of $0.26 exceeded the $0.21 estimate by 23.8%, and April EPS of negative $0.23 was better than the negative $0.38 estimate by 39.5%. Analysts listed 2 Buys, 12 Holds and 1 Sell, with an average target of $13.5221. The repeated beats offer evidence of stabilization, but the balance-sheet and profitability metrics still argue for a speculative recovery profile.
Market cap: $51.3B · Quality grade: B · Analyst consensus: Hold (avg target $92.30)
What they do. Corteva operates through Seed and Crop Protection segments. Its Seed business develops germplasm, traits and digital solutions designed to improve yield, resilience and farmer decision-making, while Crop Protection sells herbicides, insecticides, nitrogen stabilizers, seed-applied technologies and products addressing weeds, pests and disease. The company serves agricultural markets across North America, Latin America, Europe, Asia Pacific, the Middle East and Africa.
Why it fits. Corteva combines two of the most important higher-value layers of crop inputs: seed genetics and crop protection. That mix gives investors exposure to products intended to improve yield as well as protect it, rather than relying solely on nutrient pricing. The announced plan to separate Seed and Crop Protection into two standalone public companies is a significant portfolio-development factor; if completed as planned, it could give investors clearer visibility into the economics of each business.
Numbers that matter. Revenue declined 1.2% year over year and earnings declined 9.9%, although the company produced a 49.5% gross margin and 30.13% operating margin. Net margin was 5.66%, with ROE of 4.26% and ROA of 4.55%. Trailing P/E was 46.4727 and forward P/E was 21.5517, while TTM EPS of $1.65 compares with an estimated next-year EPS of $3.405. The premium trailing multiple reflects the market’s expectations for earnings improvement, not current growth acceleration.
Recent momentum. Corteva beat EPS estimates in 6 of the last 8 reported quarters. EPS of $2.30 on July 30, 2026, exceeded the $2.24 estimate by 2.7%, following a 27.1% beat in May. The analyst breakdown showed 5 Buys and 6 Holds, with no reported Sell count, and the average target was $92.30. Recent execution is constructive, but the modest revenue decline and valuation leave the planned separation and future earnings delivery central to the investment case.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
What they do. Intrepid Potash produces and delivers potassium, magnesium, sulfur, salt and water products through Potash, Trio and Oilfield Solutions segments. Its offerings include muriate of potash for agriculture, animal feed and industrial uses, plus Trio, a specialty fertilizer combining potassium, sulfate and magnesium in one particle. The company also sells salt, magnesium chloride, brines and metal-recovery salts, giving it a broader product mix than a single-nutrient producer.
Why it fits.IPI offers direct exposure to potash and specialty crop nutrition, including the multi-nutrient Trio product. Its smaller scale creates more concentrated operating leverage to fertilizer demand and pricing than a diversified platform, while the Oilfield Solutions segment and industrial, feed and deicing applications provide additional end markets. That product breadth is useful, but the company remains materially more sensitive to operational and commodity swings than larger diversified peers.
Numbers that matter. Revenue declined 1.5% year over year, but earnings growth was 382.3%. Gross margin was 27.8%, operating margin was 2.52% and net margin was 10.89%, while ROE and ROA were 3.13% and 2.07%, respectively. TTM EPS was $1.20, compared with estimated next-year EPS of $0.8405, and the trailing P/E was 30.5167. The forward P/E of 126.5823 signals that current earnings expectations are not a simple continuation of recent momentum.
Recent momentum.IPI beat estimates in 6 of the last 8 reported quarters. The August 4, 2026, report showed EPS of $0.56 versus an estimate of $0.38, a 47.4% surprise, while the May quarter beat by 29.2%. The analyst-consensus field carried a score of 1 and an average target of $36.50, without a reported Buy, Hold or Sell count. Earnings delivery has improved sharply across the latest reports, but the small market capitalization and high forward P/E make volatility an important part of the thesis.
What they do. CVR Partners produces and sells nitrogen fertilizer in the United States, focusing on ammonia and urea ammonium nitrate products. It serves agricultural and industrial customers through a concentrated production model rather than a broad retail network. That makes UAN a relatively pure-play nitrogen-fertilizer exposure, with results tied closely to realized nitrogen prices, production performance and the cost structure supporting its facilities.
Why it fits. Nitrogen is one of the core nutrient categories required to support crop yields, and UAN provides direct exposure to ammonia and urea ammonium nitrate demand. Its focused model can produce substantial upside when nitrogen markets are favorable, but it also lacks the retail, phosphate, potash and crop-protection diversification available at larger input platforms. Investors should therefore treat the partnership as a high-operating-leverage fertilizer vehicle rather than a complete agricultural-input portfolio.
Numbers that matter. Revenue grew 20.0% year over year and earnings growth was 99.9%. UAN reported a 46.4% gross margin, 42.38% operating margin and 23.67% net margin, alongside ROE of 48.3% and ROA of 11.72%. TTM EPS was $15.17, while the reported trailing P/E was 8.1411 and forward P/E was 10.2041. These figures show unusually strong profitability for the group, but they also reflect the cyclical economics of nitrogen fertilizer.
Recent momentum. The available earnings history records a 2-of-3 beat rate. Reported EPS was $7.33 on July 29, 2026, following EPS of $4.7221 on May 4 and a negative $0.97 result on February 18. The analyst-consensus field did not provide a consensus rating or count breakdown, so the investment case rests more heavily on operating profitability and nitrogen-market conditions than on broad analyst coverage. That limited coverage is itself relevant for investors evaluating a smaller partnership.
Pick #2Premium members only
Premium members see this pick's full breakdown — investment thesis, key financial metrics, recent earnings execution, and analyst consensus.
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
The ranking combines the supplied composite quality grade with profitability, growth, valuation, earnings consistency, balance-sheet indicators and analyst sentiment. We constrained the universe to US-listed fertilizer and crop-input companies with market capitalization above $500 million, then ranked the final seven by overall investment quality rather than by expected price performance alone. Company descriptions and recent results were used to distinguish upstream nutrient producers from crop-protection, seed, retail and consumer-input businesses. The article is refreshed monthly, so grades, estimates, market capitalization and analyst views can change as new financial data and earnings reports become available.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
